YSB

YSB EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of YSB (9885.HK) as of Nov 6, 2026 is 0.83 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -1.47 % — a change of -156.63% (higher).

EBIT/Assets

0.83 %

YoY

-156.63%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of YSB is 2025 0.83 % . Operating Income to Assets Ratio (EBIT/Assets) of YSB was 2024 -1.47 % . It decreases by -156.63% higher compared to the previous year.

The YSB EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2020
-11.65 CNY
Jan 1, 2021
-12.09 CNY
Jan 1, 2022
-6.31 CNY
Jan 1, 2023
-1.34 CNY
Jan 1, 2024
-1.47 CNY
Jan 1, 2025
0.83 CNY
The YSB EBIT/Assets history
YEAREBIT/AssetsYoY
0.83 %-156.63%
-1.47 %+9.67%
-1.34 %-78.70%
-6.31 %-47.82%
-12.09 %+3.78%
-11.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

YSB Stock analysis

What does YSB do? YSB, Inc. generates revenue through the wholesale and retail of pharmaceuticals and healthcare products via offline and online platforms. The company operates an online platform enabling pharmaceutical distributors to sell their products, while also offering software-as-a-service (SaaS) solutions to pharmacies. Additionally, YSB sells smart unmanned pharmaceutical booths to third-party pharmacies and provides maintenance and technical support services for these booths. The firm's primary market is domestic, serving pharmacies, distributors, and primary medical institutions through its SaaS and testing services. The company's SaaS solutions target pharmacies, helping them manage operations, while the smart unmanned pharmaceutical booths are sold to third-party pharmacies for retail distribution. Medical testing services are provided directly to primary medical institutions, and the firm's online platform connects distributors with buyers. All services and products are focused on the domestic market, with no international operations mentioned in the description. YSB, Inc. makes money by selling pharmaceuticals and healthcare products through its platforms, offering SaaS to pharmacies, and providing maintenance services for smart booths. The firm's revenue streams include direct sales of products, SaaS subscriptions, booth sales, and technical support contracts. Primary customers are pharmacies, distributors, and primary medical institutions, all operating within China's domestic market. YSB is one of the most popular companies on Eulerpool.

Frequently Asked Questions about YSB stock

Operating Income to Assets Ratio (EBIT/Assets) of YSB is 0.83 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of YSB changed from -1.47 % to 0.83 %, representing a -156.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) YSB since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s YSB with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — YSB

All Key Metrics — YSB